STOCK TITAN

Inovio Pharmaceuticals (INO) Stock News

INO NASDAQ

Inovio Pharmaceuticals reports developments in DNA medicines for HPV-related diseases, cancer and infectious diseases. Its updates center on INO-3107, a DNA immunotherapy candidate for recurrent respiratory papillomatosis, including clinical data, scientific publications, FDA review milestones and presentations at medical and biotechnology conferences.

Company news also includes quarterly and annual financial results, business updates, research on DNA-encoded monoclonal antibodies and DNA-encoded protein technology, collaboration activity and capital-structure actions involving common stock, warrants and at-the-market financing programs.

Rhea-AI Summary

INOVIO Pharmaceuticals (Nasdaq: INO) priced an underwritten public offering expected to raise approximately $75 million in gross proceeds.

The offering includes 58,747,235 common shares at $1.05 each and pre-funded warrants to purchase 12,681,337 shares at $1.049 per warrant, before underwriting discounts and commissions. Underwriters have a 30-day option to purchase up to 10,714,285 additional shares. INOVIO expects closing on or about November 9, 2026, subject to customary closing conditions. Expected gross proceeds exclude offering expenses, underwriting discounts and commissions, and any exercise of the additional-share option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

INOVIO Pharmaceuticals (Nasdaq: INO) plans to sell shares of its common stock through an underwritten public offering, subject to market conditions.

All shares in the proposed offering will be sold by INOVIO. The company intends to grant underwriters a 30-day option to purchase additional shares totaling up to 15% of the shares offered, on the same terms and conditions. Jefferies and Piper Sandler are joint book-running managers. Whether or when the offering will be completed, and its actual size and terms, remain uncertain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

INOVIO (NASDAQ: INO) will release its third quarter 2026 financial results after the market close on November 10, 2026. A live conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a general business update. The webcast will be available on the company’s website, with a replay available for 90 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.17%
Tags
earnings date
Rhea-AI Summary

INOVIO (INO) will participate in scientific conferences covering hypophosphatasia and hemophilia in New York and Montreal in November.

The company will present on rare disease protein replacement therapeutics at the Soft Bones meeting on November 8 and on INO-D001 for Hemophilia A at the World Federation of Hemophilia workshop on November 12. Abstracts and presentations will be added to its events page if available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.17%
Tags
conferences
-
Rhea-AI Summary

INOVIO (INO) received FDA accelerated approval for VOCERYQ to reduce surgery frequency in adults with recurrent respiratory papillomatosis (RRP).

Approval was based on complete response, meaning no surgical intervention for 12 months after treatment. In the RRP-001 efficacy population, 7 of 26 patients (27%) required no surgical papilloma excision during 12 months of follow-up; these patients had required at least three surgeries in the preceding year. VOCERYQ was approved in combination with INOVIO's CELLECTRA 5PSP delivery device.

Continued approval may depend on confirmation of clinical benefit. The FDA requires a draft confirmatory-study protocol by the end of 2026, with final protocol alignment expected by mid-2027. INOVIO expects ordering and shipping in approximately 60 days and a full commercial launch in the first quarter of 2027. Label warnings cover injection-site reactions and delivery-procedure risks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
213.75%
Tags
-
Rhea-AI Summary

INOVIO Pharmaceuticals (Nasdaq: INO) secured an $80,416,101 judgment in its favor against VGXI and GeneOne Life Science on all its claims.

The Court of Common Pleas of Montgomery County, Pennsylvania, awarded $61,750,789 in compensatory damages and $18,665,312 in fees and costs. It also entered judgment against the defendants on their counterclaims. The case was filed on June 3, 2020. INOVIO expects the defendants' financial condition to impair collection of some or all of the judgment and intends to make every reasonable effort to recover the damages awarded.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.26%
Tags
none
Rhea-AI Summary

INOVIO (NASDAQ: INO) announced participation in two investor events in New York. The company will join the Cantor Global Healthcare Conference on Wednesday, September 9, featuring a fireside chat at 3:20 PM ET with a live webcast. INOVIO will also present at the H.C. Wainwright 28th Annual Global Investment Conference, with a virtual presentation available starting Friday, September 11 at 7:00 AM ET. Webcast and virtual links will host replays for 90 days, and management plans to hold one-on-one meetings with investors during both conferences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
conferences
-
Rhea-AI Summary

Inovio (NASDAQ: INO) reported second quarter 2026 results and pipeline progress. The FDA review of its BLA for INO-3107 in recurrent respiratory papillomatosis is advancing under the accelerated approval program, with a PDUFA target date of October 30, 2026, following a late-cycle meeting and completion of all scheduled pre-licensure inspections. Inovio is preparing U.S. commercial launch infrastructure and has engaged Syneos Health for MSLs and contract sales support.

Partner ApolloBio’s pivotal Phase 3 trial of VGX-3100 in cervical dysplasia met its primary efficacy endpoint with favorable safety in China. Q2 2026 R&D and G&A expenses fell to $10.8 million and $7.8 million, respectively, reducing total operating expenses to $18.6 million. Net loss narrowed to $6.0 million versus $23.5 million a year earlier, mainly from a $13.9 million non-cash warrant liability gain. Cash, cash equivalents and short-term investments were $36.7 million at June 30, 2026, excluding $18.3 million in net proceeds from a July equity offering, and are expected to fund operations into late Q1 2027, including a potential INO-3107 launch, if approved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.90%
Tags
-
Rhea-AI Summary

INOVIO (NASDAQ: INO) will release its second quarter 2026 financial results after the market close on August 12, 2026. The company will host a live, listen-only conference call and webcast at 4:30 p.m. ET to review the results and provide a general business update. The webcast, including a live Q&A with analysts, will be accessible via INOVIO's investor relations website and will remain available as an archived replay for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.10%
Tags
earnings date
Rhea-AI Summary

INOVIO (Nasdaq: INO) priced an underwritten public offering of 21,052,632 common shares and accompanying warrants to purchase up to 42,105,264 shares (or pre-funded warrants) at a combined public price of $0.95 per share and two warrants, with a warrant exercise price of $1.10 per share.

According to INOVIO, the underwriter has a 30-day option to buy up to 3,157,894 additional shares and/or warrants to purchase 6,315,788 shares. All securities are being sold by the company, which expects gross proceeds of approximately $20.0 million before fees, with closing anticipated around July 31, 2026. Piper Sandler is sole manager.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.92%
Tags

FAQ

What is the current stock price of Inovio Pharmaceuticals (INO)?

Inovio Pharmaceuticals (INO) last closed at $1.22.

What is the market cap of Inovio Pharmaceuticals (INO)?

The market cap of Inovio Pharmaceuticals (INO) is approximately $133.9M.